Good Life Advisors LLC Sells 429 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Good Life Advisors LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,675 shares of the biopharmaceutical company’s stock after selling 429 shares during the quarter. Good Life Advisors LLC’s holdings in Gilead Sciences were worth $298,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Altfest L J & Co. Inc. bought a new position in Gilead Sciences during the fourth quarter worth about $210,000. Cornell Pochily Investment Advisors Inc. boosted its position in shares of Gilead Sciences by 12.6% in the fourth quarter. Cornell Pochily Investment Advisors Inc. now owns 14,708 shares of the biopharmaceutical company’s stock valued at $1,192,000 after acquiring an additional 1,642 shares during the period. Procyon Advisors LLC boosted its position in shares of Gilead Sciences by 4.4% in the fourth quarter. Procyon Advisors LLC now owns 30,277 shares of the biopharmaceutical company’s stock valued at $2,453,000 after acquiring an additional 1,263 shares during the period. Planned Solutions Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $182,000. Finally, Tectonic Advisors LLC boosted its position in shares of Gilead Sciences by 6.2% in the fourth quarter. Tectonic Advisors LLC now owns 49,865 shares of the biopharmaceutical company’s stock valued at $4,040,000 after acquiring an additional 2,903 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the sale, the insider now owns 82,729 shares in the company, valued at approximately $7,050,992.67. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the completion of the transaction, the insider now directly owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,242 shares of company stock worth $1,277,726. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ GILD opened at $73.25 on Friday. The company has a market cap of $91.20 billion, a price-to-earnings ratio of 16.28, a PEG ratio of 0.92 and a beta of 0.18. The firm’s fifty day moving average is $75.11 and its 200 day moving average is $77.29. Gilead Sciences, Inc. has a 52 week low of $71.37 and a 52 week high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter last year, the firm earned $1.67 EPS. The business’s revenue was down 3.7% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.20%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is 68.44%.

Analyst Ratings Changes

A number of equities analysts have recently commented on GILD shares. Oppenheimer cut their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, February 12th. Cantor Fitzgerald cut their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Wells Fargo & Company lowered their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Royal Bank of Canada lowered their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 14th. Finally, Barclays lowered their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $85.36.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.